Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for TRVI
| Stock Name | Trevi Therapeutics Inc |
| Ticker | TRVI(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US89532M1018 |
Show aggregate TRVI holdings
News associated with TRVI
- Raymond James Financial Cuts Trevi Therapeutics (NASDAQ:TRVI) Price Target to $27.00
- Trevi Therapeutics (NASDAQ:TRVI – Free Report) had its price objective trimmed by Raymond James Financial from $29.00 to $27.00 in a report published on Friday morning,Benzinga reports. The firm currently has a strong-buy rating on the stock. Several other equities analysts have also commented on TRVI. D. Boral Capital restated a “buy” rating and set […] - 2025-08-11 02:14:44
- Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $20.88
- Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. The average twelve-month target price among brokerages […] - 2025-07-24 05:54:56
- Oppenheimer & Co. Inc. Increases Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)
- Oppenheimer & Co. Inc. increased its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 23.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 100,437 shares of the company’s stock after purchasing an additional 19,034 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Trevi Therapeutics were worth $632,000 at […] - 2025-07-01 05:02:56
- Trevi Therapeutics (NASDAQ:TRVI) Cut to “Sell” at Wall Street Zen
- Wall Street Zen lowered shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) from a hold rating to a sell rating in a report published on Friday. Other analysts also recently issued reports about the stock. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target […] - 2025-06-09 02:51:00
- Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock
- (RTTNews) - Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio - oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis - IPF and refractory chronic cough - RCC patients, announced the pricing of its previously - 2025-06-04 22:43:19
- ProShare Advisors LLC Has $85,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)
- ProShare Advisors LLC raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 86.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,685 shares of the company’s stock after buying an additional 9,589 shares during the […] - 2025-06-04 04:40:48
- D. Boral Capital Reaffirms “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI)
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 252.94% from the stock’s current price. […] - 2025-06-04 03:14:44
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $18.63 Average PT from Analysts
- Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that […] - 2025-06-04 02:36:50
- Trevi Therapeutics (NASDAQ:TRVI) Now Covered by HC Wainwright
- HC Wainwright began coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note published on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $21.00 price objective on the stock. A number of other analysts have also recently commented on TRVI. Oppenheimer boosted their price objective on […] - 2025-05-29 03:08:47
- Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from Needham & Company LLC
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 288.35% from […] - 2025-05-22 02:44:46
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by Algert Global LLC
- Algert Global LLC lessened its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 39.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 14,779 shares of the company’s stock after selling 9,810 shares during the period. Algert Global LLC’s holdings in Trevi Therapeutics were worth $61,000 as of its most recent filing with […] - 2025-05-14 05:59:09
- MetLife Investment Management LLC Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)
- MetLife Investment Management LLC grew its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 104.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 38,785 shares of the company’s stock after purchasing an additional 19,857 shares during the period. MetLife Investment Management LLC’s holdings in Trevi Therapeutics were worth […] - 2025-05-09 05:00:47
- Marshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)
- Marshall Wace LLP lessened its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 47.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 42,921 shares of the company’s stock after selling 38,203 shares during the quarter. Marshall Wace LLP’s holdings in Trevi Therapeutics were worth $177,000 at the end of […] - 2025-05-06 05:22:47
- Trevi Therapeutics Target of Unusually Large Options Trading (NASDAQ:TRVI)
- Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 2,815 call options on the stock. This is an increase of 240% compared to the typical volume of 828 call options. Insiders Place Their Bets In related news, CEO Jennifer L. Good sold […] - 2025-04-11 02:39:04
- Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from HC Wainwright
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.50 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 89.11% from the company’s current price. TRVI has been […] - 2025-03-21 05:10:56
- Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at Needham & Company LLC
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target cut by stock analysts at Needham & Company LLC from $25.00 to $24.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target would indicate a potential upside of 263.09% […] - 2025-03-21 04:26:58
- Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $15.94
- Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price objective […] - 2025-03-21 03:52:50
- Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)
- Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) was the target of some unusual options trading on Tuesday. Stock investors acquired 5,103 call options on the company. This is an increase of 802% compared to the average daily volume of 566 call options. Trevi Therapeutics Price Performance Shares of NASDAQ TRVI opened at $6.30 on […] - 2025-03-12 05:42:51
- Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Upgraded by Raymond James
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a $29.00 target price on the stock, up from their prior target price of $9.00. Raymond James’ target price […] - 2025-03-12 03:56:43
- Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, Needham & Company LLC Analyst Says
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target upped by equities research analysts at Needham & Company LLC from $8.00 to $25.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of […] - 2025-03-12 03:56:43
- Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, HC Wainwright Analyst Says
- Trevi Therapeutics (NASDAQ:TRVI – Free Report) had its price target increased by HC Wainwright from $7.50 to $12.50 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. A number of other equities analysts have also issued reports on the stock. Needham & Company LLC raised their target […] - 2025-03-11 03:50:48
- Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital
- D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $21.00 target price on the stock. A number of other research analysts have also recently weighed in on TRVI. HC Wainwright lifted their […] - 2025-03-10 03:45:16
- D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
- Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 364.60% from the company’s […] - 2025-02-26 04:30:58
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) TRVI holdings
| Date | Number of TRVI Shares Held | Base Market Value of TRVI Shares | Local Market Value of TRVI Shares | Change in TRVI Shares Held | Change in TRVI Base Value | Current Price per TRVI Share Held | Previous Price per TRVI Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of TRVI by Blackrock for IE00BYXG2H39
Show aggregate share trades of TRVI| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-06 | BUY | 609 | 9.950 | 10.138 | 10.119 | USD 6,163 | 6.19 |
| 2025-10-03 | BUY | 1,414 | 9.880 | 9.990 | 9.979 | USD 14,110 | 6.17 |
| 2025-10-02 | BUY | 202 | 9.560 | 9.620 | 9.614 | USD 1,942 | 6.15 |
| 2025-09-30 | BUY | 404 | 9.150 | 9.290 | 9.276 | USD 3,748 | 6.12 |
| 2025-09-26 | BUY | 406 | 8.770 | 8.920 | 8.905 | USD 3,615 | 6.09 |
| 2025-09-25 | BUY | 406 | 8.460 | 8.740 | 8.712 | USD 3,537 | 6.08 |
| 2025-09-24 | BUY | 8,706 | 8.470 | 8.540 | 8.533 | USD 74,288 | 6.06 |
| 2025-09-18 | BUY | 178 | 8.540 | 8.560 | 8.558 | USD 1,523 | 6.05 |
| 2025-09-17 | BUY | 537 | 7.980 | 8.230 | 8.205 | USD 4,406 | 6.04 |
| 2025-09-11 | SELL | -177 | 9.750 | 9.920 | 9.903 | USD -1,753 | 5.98  Loss of -694 on sale |
| 2025-09-10 | BUY | 356 | 9.620 | 9.810 | 9.791 | USD 3,486 | 5.96 |
| 2025-09-05 | SELL | -178 | 7.010 | 7.320 | 7.289 | USD -1,297 | 5.93 Loss of -242 on sale |
| 2025-08-29 | SELL | -534 | 7.255 | 7.520 | 7.493 | USD -4,002 | 5.90 Loss of -853 on sale |
| 2025-08-27 | BUY | 354 | 8.000 | 8.780 | 8.702 | USD 3,081 | 5.88 |
| 2025-08-26 | SELL | -177 | 7.420 | 7.450 | 7.447 | USD -1,318 | 5.87 Loss of -280 on sale |
| 2025-08-25 | BUY | 177 | 7.280 | 7.690 | 7.649 | USD 1,354 | 5.86 |
| 2025-08-20 | SELL | -708 | 7.420 | 7.510 | 7.501 | USD -5,311 | 5.84 Loss of -1,178 on sale |
| 2025-08-18 | BUY | 352 | 7.450 | 7.600 | 7.585 | USD 2,670 | 5.82 |
| 2025-08-08 | SELL | -352 | 7.420 | 7.470 | 7.465 | USD -2,628 | 5.76 Loss of -599 on sale |
| 2025-08-05 | BUY | 176 | 7.410 | 7.490 | 7.482 | USD 1,317 | 5.73 |
| 2025-08-01 | SELL | -527 | 7.330 | 7.570 | 7.546 | USD -3,977 | 5.71 Loss of -968 on sale |
| 2025-07-30 | BUY | 704 | 7.420 | 7.740 | 7.708 | USD 5,426 | 5.69 |
| 2025-07-17 | SELL | -352 | 6.840 | 7.030 | 7.011 | USD -2,468 | 5.57 Loss of -506 on sale |
| 2025-07-11 | SELL | -1,416 | 6.550 | 6.595 | 6.590 | USD -9,332 | 5.54 Loss of -1,492 on sale |
| 2025-07-07 | BUY | 531 | 5.950 | 6.070 | 6.058 | USD 3,217 | 5.52 |
| 2025-07-02 | BUY | 9,790 | 5.980 | 6.075 | 6.065 | USD 59,381 | 5.51 |
| 2025-06-25 | BUY | 354 | 5.680 | 5.780 | 5.770 | USD 2,043 | 5.50 |
| 2025-06-20 | BUY | 8,140 | 5.960 | 6.185 | 6.162 | USD 50,163 | 5.50 |
| 2025-06-11 | BUY | 302 | 6.250 | 6.580 | 6.547 | USD 1,977 | 5.45 |
| 2025-06-10 | BUY | 302 | 6.510 | 6.569 | 6.563 | USD 1,982 | 5.44 |
| 2025-06-04 | SELL | -151 | 6.580 | 6.590 | 6.589 | USD -995 | 5.40 Loss of -180 on sale |
| 2025-04-23 | BUY | 150 | 6.270 | 6.450 | 6.432 | USD 965 | 4.98 |
| 2025-04-10 | SELL | -1,200 | 5.280 | 5.320 | 5.316 | USD -6,379 | 4.85 Loss of -563 on sale |
| 2025-04-08 | SELL | -149 | 5.300 | 6.060 | 5.984 | USD -892 | 4.83 Loss of -172 on sale |
| 2025-04-07 | SELL | -149 | 5.780 | 6.150 | 6.113 | USD -911 | 4.82 Loss of -193 on sale |
| 2025-04-04 | SELL | -750 | 6.050 | 6.105 | 6.100 | USD -4,575 | 4.80 Loss of -977 on sale |
| 2025-04-01 | BUY | 612 | 6.010 | 6.230 | 6.208 | USD 3,799 | 4.75 |
| 2025-03-31 | SELL | -453 | 6.290 | 6.500 | 6.479 | USD -2,935 | 4.73 Loss of -794 on sale |
| 2025-03-21 | BUY | 7,811 | 6.470 | 6.620 | 6.605 | USD 51,592 | 4.53 |
| 2025-03-14 | SELL | -2,016 | 6.750 | 6.780 | 6.777 | USD -13,662 | 4.30 Loss of -4,987 on sale |
| 2025-03-07 | SELL | -252 | 4.300 | 4.550 | 4.525 | USD -1,140 | 4.12 Loss of -101 on sale |
| 2025-03-04 | SELL | -126 | 4.440 | 4.520 | 4.512 | USD -569 | 4.10 Loss of -51 on sale |
| 2025-02-25 | BUY | 252 | 4.520 | 4.540 | 4.538 | USD 1,144 | 4.05 |
| 2025-02-19 | SELL | -126 | 4.570 | 4.590 | 4.588 | USD -578 | 3.99 Loss of -76 on sale |
| 2025-02-13 | BUY | 378 | 4.010 | 4.140 | 4.127 | USD 1,560 | 3.97 |
| 2025-02-12 | BUY | 126 | 4.050 | 4.085 | 4.082 | USD 514 | 3.97 |
| 2025-02-11 | BUY | 504 | 3.960 | 4.040 | 4.032 | USD 2,032 | 3.97 |
| 2025-01-17 | BUY | 504 | 3.760 | 3.820 | 3.814 | USD 1,922 | 3.97 |
| 2025-01-16 | BUY | 504 | 3.780 | 3.890 | 3.879 | USD 1,955 | 4.00 |
| 2025-01-10 | SELL | -252 | 3.820 | 4.070 | 4.045 | USD -1,019 | 4.14  Profit of 24 on sale |
| 2025-01-08 | SELL | -504 | 4.030 | 4.360 | 4.327 | USD -2,181 | 4.36 Profit of 17 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of TRVI
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 453,190 | 0 | 630,136 | 71.9% |
| 2025-09-18 | 419,875 | 0 | 624,503 | 67.2% |
| 2025-09-17 | 259,147 | 651 | 395,789 | 65.5% |
| 2025-09-16 | 524,519 | 0 | 731,027 | 71.8% |
| 2025-09-15 | 778,078 | 34,664 | 1,565,064 | 49.7% |
| 2025-09-12 | 610,083 | 23,293 | 1,598,398 | 38.2% |
| 2025-09-11 | 697,547 | 0 | 1,142,726 | 61.0% |
| 2025-09-10 | 1,685,738 | 112,956 | 4,090,909 | 41.2% |
| 2025-09-09 | 1,171,318 | 25,763 | 2,954,193 | 39.6% |
| 2025-09-08 | 720,191 | 0 | 1,863,937 | 38.6% |
| 2025-09-05 | 206,828 | 0 | 699,016 | 29.6% |
| 2025-09-04 | 309,904 | 22,651 | 529,678 | 58.5% |
| 2025-09-03 | 307,661 | 3,931 | 576,715 | 53.3% |
| 2025-09-02 | 284,514 | 0 | 446,221 | 63.8% |
| 2025-08-29 | 200,412 | 6,088 | 479,728 | 41.8% |
| 2025-08-28 | 626,784 | 11,321 | 1,105,093 | 56.7% |
| 2025-08-27 | 1,667,721 | 18,059 | 3,261,550 | 51.1% |
| 2025-08-26 | 191,804 | 0 | 342,434 | 56.0% |
| 2025-08-25 | 332,568 | 0 | 499,469 | 66.6% |
| 2025-08-22 | 246,509 | 0 | 451,414 | 54.6% |
| 2025-08-21 | 426,992 | 8,400 | 732,551 | 58.3% |
| 2025-08-20 | 119,812 | 0 | 235,698 | 50.8% |
| 2025-08-19 | 194,595 | 0 | 365,342 | 53.3% |
| 2025-08-18 | 183,690 | 0 | 367,890 | 49.9% |
| 2025-08-15 | 166,356 | 0 | 299,719 | 55.5% |
| 2025-08-14 | 222,158 | 0 | 377,671 | 58.8% |
| 2025-08-13 | 232,127 | 0 | 538,778 | 43.1% |
| 2025-08-12 | 278,685 | 0 | 565,519 | 49.3% |
| 2025-08-11 | 313,975 | 6,565 | 580,399 | 54.1% |
| 2025-08-08 | 319,471 | 17,582 | 731,388 | 43.7% |
| 2025-08-07 | 253,198 | 0 | 406,324 | 62.3% |
| 2025-08-06 | 244,985 | 0 | 405,225 | 60.5% |
| 2025-08-05 | 154,850 | 0 | 333,182 | 46.5% |
| 2025-08-04 | 202,487 | 0 | 310,248 | 65.3% |
| 2025-08-01 | 343,561 | 0 | 531,282 | 64.7% |
| 2025-07-31 | 187,982 | 0 | 287,257 | 65.4% |
| 2025-07-30 | 435,153 | 0 | 724,722 | 60.0% |
| 2025-07-29 | 325,821 | 0 | 504,355 | 64.6% |
| 2025-07-28 | 547,974 | 9 | 904,638 | 60.6% |
| 2025-07-25 | 312,925 | 0 | 509,149 | 61.5% |
| 2025-07-24 | 719,559 | 0 | 1,871,956 | 38.4% |
| 2025-07-23 | 728,292 | 1,480 | 2,181,203 | 33.4% |
| 2025-07-22 | 319,664 | 111 | 913,633 | 35.0% |
| 2025-07-21 | 253,886 | 0 | 438,916 | 57.8% |
| 2025-07-18 | 319,575 | 0 | 1,231,605 | 25.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy